We have successfully addressed all drawbacks associated with currently used SCS, enhancing efficacy, patient comfort, meeting healthcare system requirements, and aligning with the needs of key industry players. Our invention not only promises sustainable and effective chronic pain treatment but also presents opportunities in neurorehabilitation, neurorestoration, spasticity, Parkinson’s, Refractory Angina Pectoris, and various other neurological disorders.

Spinally is not only about stimulation. Our lead delivers unparalleled quality in neural signal recording, opening the door to personalized therapy.

FuturaLeadT™ can measure, among other parameters, the Evoked Compound Action Potentials (ECAPs), which stands as the sole viable stance to enhance treatment efficiency through a closed-loop approach.

Standard electrodes are implanted epidurally, meaning they are placed outside the dura mater. This requires the electric current to pass through several layers of tissue, before reaching the spinal cord. As a result, about 90% of the energy is lost or dispersed along this path. Existing spinal cord stimulation devices consuming a significant amount of energy while having limited capacity to deliver it effectively. Consequently, stimulation only reaches the superficial layer of the posterior columns, without affecting deeper axons, which greatly hampers efficacy.